|
1
|
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
|
J Clin Oncol
|
2011
|
2.45
|
|
2
|
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.
|
J Clin Oncol
|
2012
|
2.36
|
|
3
|
Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
|
Eur Urol
|
2008
|
2.34
|
|
4
|
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.
|
Hum Mol Genet
|
2006
|
2.23
|
|
5
|
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.
|
Eur Urol
|
2007
|
2.21
|
|
6
|
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
|
Eur Urol
|
2008
|
2.02
|
|
7
|
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
|
J Clin Oncol
|
2005
|
1.93
|
|
8
|
Active surveillance is the preferred approach to clinical stage I testicular cancer.
|
J Clin Oncol
|
2013
|
1.81
|
|
9
|
Treatment of penile strangulation caused by constricting devices.
|
Urology
|
2002
|
1.81
|
|
10
|
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
|
Eur Urol
|
2013
|
1.75
|
|
11
|
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.
|
Urol Oncol
|
2009
|
1.70
|
|
12
|
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
|
Eur Urol
|
2012
|
1.69
|
|
13
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
Eur Urol
|
2012
|
1.64
|
|
14
|
Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review.
|
J Clin Oncol
|
2003
|
1.63
|
|
15
|
Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
|
Eur Urol
|
2011
|
1.52
|
|
16
|
Organ-sparing surgery for adult testicular tumours: a systematic review of the literature.
|
Eur Urol
|
2010
|
1.43
|
|
17
|
Histopathological and molecular features of late relapses in non-seminomas.
|
BJU Int
|
2010
|
1.40
|
|
18
|
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
|
Eur Urol
|
2007
|
1.37
|
|
19
|
Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases.
|
J Urol
|
2005
|
1.32
|
|
20
|
Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.
|
Pharmacogenet Genomics
|
2011
|
1.27
|
|
21
|
Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
|
J Urol
|
2007
|
1.26
|
|
22
|
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
|
J Clin Oncol
|
2003
|
1.19
|
|
23
|
Testicular germ cell tumors: pathogenesis, diagnosis and treatment.
|
Nat Rev Endocrinol
|
2010
|
1.12
|
|
24
|
Analysis of microdissected prostate tissue with ProteinChip arrays--a way to new insights into carcinogenesis and to diagnostic tools.
|
Int J Mol Med
|
2002
|
1.11
|
|
25
|
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology.
|
Eur J Cancer
|
2010
|
1.10
|
|
26
|
Quality criteria of laparoscopic nephroureterectomy.
|
Eur Urol
|
2007
|
1.07
|
|
27
|
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors.
|
Genes Chromosomes Cancer
|
2008
|
1.05
|
|
28
|
Contemporary management of postchemotherapy testis cancer.
|
Eur Urol
|
2012
|
1.05
|
|
29
|
Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
|
Hum Gene Ther
|
2003
|
1.04
|
|
30
|
Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk.
|
Arch Toxicol
|
2012
|
1.04
|
|
31
|
MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
|
Eur Radiol
|
2014
|
1.04
|
|
32
|
Late relapse of testicular cancer.
|
World J Urol
|
2004
|
1.03
|
|
33
|
Sunitinib for the treatment of metastatic renal cell carcinoma.
|
Cancer Treat Rev
|
2011
|
1.01
|
|
34
|
Does lung surfactant promote disaggregation of nanostructured titanium dioxide?
|
J Occup Environ Med
|
2006
|
1.01
|
|
35
|
Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk.
|
Arch Toxicol
|
2010
|
1.00
|
|
36
|
Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
|
J Urol
|
2003
|
0.97
|
|
37
|
Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.
|
Clin Genitourin Cancer
|
2012
|
0.97
|
|
38
|
Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer.
|
Int J Oncol
|
2005
|
0.95
|
|
39
|
Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society.
|
Urol Int
|
2010
|
0.94
|
|
40
|
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
|
BJU Int
|
2014
|
0.94
|
|
41
|
CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer.
|
J Urol
|
2009
|
0.93
|
|
42
|
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
|
Urol Oncol
|
2012
|
0.92
|
|
43
|
Canadian consensus guidelines for the management of testicular germ cell cancer.
|
Can Urol Assoc J
|
2010
|
0.92
|
|
44
|
Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
|
BJU Int
|
2009
|
0.92
|
|
45
|
Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.
|
Cancer Immunol Immunother
|
2002
|
0.91
|
|
46
|
Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.
|
J Urol
|
2008
|
0.91
|
|
47
|
Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene.
|
Arch Toxicol
|
2011
|
0.89
|
|
48
|
Preparation, testing and characterization of doped TiO2 active in the peroxidation of biomolecules under visible light.
|
J Phys Chem B
|
2005
|
0.87
|
|
49
|
Comparison of different mathematical models of diffusion-weighted prostate MR imaging.
|
Magn Reson Imaging
|
2012
|
0.87
|
|
50
|
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
|
BJU Int
|
2014
|
0.86
|
|
51
|
Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options.
|
Oncology
|
2008
|
0.86
|
|
52
|
Extraperitoneal laparo-endoscopic single-site radical prostatectomy: first experience.
|
World J Urol
|
2010
|
0.85
|
|
53
|
Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
|
J Urol
|
2004
|
0.85
|
|
54
|
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
|
Clin Genitourin Cancer
|
2013
|
0.85
|
|
55
|
Structure determination of adsorbed hydrogen on a real catalyst.
|
Chem Commun (Camb)
|
2010
|
0.85
|
|
56
|
Modified ureterosigmoidostomy (Mainz Pouch II) in different age groups and with different techniques of ureteric implantation.
|
BJU Int
|
2004
|
0.84
|
|
57
|
E-Learning in Urology: Implementation of the Learning and Teaching Platform CASUS® - Do Virtual Patients Lead to Improved Learning Outcomes? A Randomized Study among Students.
|
Urol Int
|
2015
|
0.83
|
|
58
|
Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors.
|
Eur Urol
|
2003
|
0.83
|
|
59
|
Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?
|
Eur Urol
|
2009
|
0.82
|
|
60
|
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.
|
Eur Urol
|
2012
|
0.82
|
|
61
|
3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization.
|
Acta Radiol
|
2013
|
0.81
|
|
62
|
Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy.
|
Eur Radiol
|
2013
|
0.81
|
|
63
|
Contractions but not AICAR increase FABPpm content in rat muscle sarcolemma.
|
Mol Cell Biochem
|
2009
|
0.81
|
|
64
|
Retroperitoneal lymph node dissection after chemotherapy.
|
BJU Int
|
2009
|
0.81
|
|
65
|
Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
|
Eur Urol
|
2011
|
0.81
|
|
66
|
Health-related quality-of-life following modified ureterosigmoidostomy (Mainz Pouch II) as continent urinary diversion.
|
Eur Urol
|
2004
|
0.80
|
|
67
|
Complete assignment of the vibrational modes of C60 by inelastic neutron scattering spectroscopy and periodic-DFT.
|
Phys Chem Chem Phys
|
2011
|
0.79
|
|
68
|
Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism.
|
J Steroid Biochem Mol Biol
|
2003
|
0.79
|
|
69
|
Hyperoxia-induced improvement of the in vitro response to gemcitabine in transitional cell carcinoma.
|
Anticancer Res
|
2005
|
0.78
|
|
70
|
Do we need the final results of the ERSPC trial?
|
Eur Urol
|
2006
|
0.78
|
|
71
|
Radiofrequency ablation of renal tumors improved by preoperative ex-vivo computer simulation model.
|
J Endourol
|
2007
|
0.78
|
|
72
|
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
|
Invest New Drugs
|
2013
|
0.78
|
|
73
|
Investigation of the glidant properties of compacted colloidal silicon dioxide by angle of repose and X-ray photoelectron spectroscopy.
|
Eur J Pharm Biopharm
|
2006
|
0.78
|
|
74
|
Words of wisdom: Re: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
|
Eur Urol
|
2013
|
0.77
|
|
75
|
Tissue engineering and reconstructive surgery in urology.
|
Eur Urol
|
2007
|
0.77
|
|
76
|
Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
|
Ger Med Sci
|
2006
|
0.77
|
|
77
|
Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer.
|
Oncol Res Treat
|
2014
|
0.77
|
|
78
|
Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
|
Anticancer Res
|
2014
|
0.76
|
|
79
|
A new form of noninvasive wound closure with a surgical zipper.
|
J Urol
|
2003
|
0.76
|
|
80
|
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
|
Oncology
|
2015
|
0.76
|
|
81
|
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.
|
Eur Urol
|
2013
|
0.76
|
|
82
|
Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity.
|
Histochem Cell Biol
|
2010
|
0.76
|
|
83
|
[In Process Citation].
|
Aktuelle Urol
|
2014
|
0.75
|
|
84
|
Volume matters--but it should be measured well!
|
Eur Urol
|
2006
|
0.75
|
|
85
|
Surgery is an essential part of salvage treatment in refractory germ cell tumors.
|
Eur Urol
|
2006
|
0.75
|
|
86
|
Loss of imprinting of the insulin-like growth factor 2 and the H19 gene in testicular seminomas detected by real-time PCR approach.
|
Arch Toxicol
|
2006
|
0.75
|
|
87
|
Editorial comment on: Comparison of complications in three incontinent urinary diversions.
|
Eur Urol
|
2008
|
0.75
|
|
88
|
Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - a pilot study.
|
Anticancer Res
|
2012
|
0.75
|
|
89
|
Editorial comment on: laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
|
Eur Urol
|
2008
|
0.75
|
|
90
|
Design of testis cancer trials: who knows best?
|
J Clin Oncol
|
2012
|
0.75
|
|
91
|
[Seminoma - high AFP serum levels - probably retroperitoneal tumor components].
|
Aktuelle Urol
|
2012
|
0.75
|
|
92
|
Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
|
Urol Oncol
|
2010
|
0.75
|
|
93
|
Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines.
|
Anticancer Res
|
2004
|
0.75
|
|
94
|
A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer.
|
Int J Mol Med
|
2005
|
0.75
|
|
95
|
The influence of ethylenediamine tetra acetic acid (EDTA) on the transformation and solubility of metallic palladium and palladium(II) oxide in the environment.
|
Environ Sci Process Impacts
|
2015
|
0.75
|
|
96
|
Corporoplasty for advanced Peyronie's disease using venous and/or dermis patch grafting: new surgical technique and long-term patient satisfaction.
|
J Urol
|
2003
|
0.75
|
|
97
|
Characterisation of the surface of freshly prepared precious metal catalysts.
|
Phys Chem Chem Phys
|
2016
|
0.75
|
|
98
|
|
Aktuelle Urol
|
2017
|
0.75
|
|
99
|
Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?
|
Urol Oncol
|
2017
|
0.75
|
|
100
|
Primary extragonadal germ cell tumor of the prostate in a young man.
|
Int J Urol
|
2004
|
0.75
|
|
101
|
Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?
|
Curr Opin Urol
|
2011
|
0.75
|
|
102
|
Interview with Professor Peter Albers: treatment developments in testicular cancer. Interview by Christine McKillop.
|
Eur Urol
|
2006
|
0.75
|